Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Sesen Bio stock price, quote, forecast and news

SESN
US8177631053
A2JL47

Price

6.53
Today +/-
+0
Today %
+0 %
P

Sesen Bio Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Sesen Bio, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Sesen Bio from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Sesen Bio’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Sesen Bio. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Sesen Bio’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Sesen Bio’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Sesen Bio’s growth potential.

Sesen Bio Revenue, EBIT and net profit per share

DateSesen Bio RevenueSesen Bio EBITSesen Bio Net Income
2028e0 undefined0 undefined-4.07 M undefined
2027e0 undefined-8.06 M undefined-4.07 M undefined
2026e0 undefined-7.75 M undefined-4.07 M undefined
2025e0 undefined-7.14 M undefined-4.07 M undefined
2024e0 undefined-6.63 M undefined-6.1 M undefined
2023e0 undefined-16.63 M undefined-18.31 M undefined
202240 M undefined13.62 M undefined-19.88 M undefined
202126.54 M undefined28.68 M undefined-336,000 undefined
202011.24 M undefined-21.08 M undefined-22.54 M undefined
20190 undefined-108.49 M undefined-107.5 M undefined
20180 undefined-34.5 M undefined-33.69 M undefined
2017425,000 undefined-29.26 M undefined-29.03 M undefined
201629.98 M undefined2.87 M undefined1.89 M undefined
2015990,000 undefined-35.2 M undefined-33.45 M undefined
20142.24 M undefined-32.93 M undefined-34.16 M undefined
20131.33 M undefined-16.2 M undefined-18.03 M undefined
20120 undefined-19.48 M undefined-19.66 M undefined
20110 undefined-12.68 M undefined-12.83 M undefined

Sesen Bio Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (k)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2011201220132014201520162017201820192020202120222023e2024e2025e2026e2027e2028e
0012029000112640000000
---100.00------136.3653.85------
------------------
000000000000000000
-12-19-16-32-352-29-34-108-212813-16-6-7-7-80
---1,600.00-1,600.00-6.90----190.91107.6932.50------
-12,000-19,000-18,000-34,000-33,0001,000-29,000-33,000-107,000-22,0000-19,000-18,000-6,000-4,000-4,000-4,000-4,000
-58.33-5.2688.89-2.94-103.03-3,000.0013.79224.24-79.44---5.26-66.67-33.33---
1.641.641.3514.6418.9921.7326.1161.7790.935.919.1210.03000000
------------------
Details

Keystats

ⓘ

Revenue and Growth

The Sesen Bio Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Sesen Bio is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Sesen Bio provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Sesen Bio's financial health and stability.

Assets

Sesen Bio's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Sesen Bio must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Sesen Bio after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Sesen Bio's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (k)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201120122013201420152016201720182019202020212022
-12,000-19,000-18,000-34,000-33,0001,000-29,000-33,000-107,000-22,0000-19,000
000000000000
000000000000
10110-200-30-4863
002303101072-9-19-18
000000000000
000000000000
-10-19-13-29-342-17-22-37-30-6824
000000000000
00000000000-53
00000000000-53
000000000000
01554-14000000
112587012075835381760
1026137516-1375835381760
---1.00---------
000000000000
-17046-17-10-1035-27107-29
000000-17.77-22.83-37.66-30.85-68.8824.9
000000000000

Sesen Bio stock margins

The Sesen Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sesen Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sesen Bio.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Sesen Bio's sales revenue. A higher gross margin percentage indicates that the Sesen Bio retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Sesen Bio's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Sesen Bio's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Sesen Bio's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Sesen Bio. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Sesen Bio's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Sesen Bio Margin History

Sesen Bio Gross marginSesen Bio Profit marginSesen Bio EBIT marginSesen Bio Profit margin
2028e0 %0 %0 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
2023e0 %0 %0 %
20220 %34.05 %-49.71 %
20210 %108.04 %-1.27 %
20200 %-187.58 %-200.64 %
20190 %0 %0 %
20180 %0 %0 %
20170 %-6,883.53 %-6,830.35 %
20160 %9.57 %6.3 %
20150 %-3,555.56 %-3,378.79 %
20140 %-1,470.09 %-1,525 %
20130 %-1,218.05 %-1,355.64 %
20120 %0 %0 %
20110 %0 %0 %

Sesen Bio Stock Sales Revenue, EBIT, Earnings per Share

The Sesen Bio earnings per share therefore indicates how much revenue Sesen Bio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Sesen Bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sesen Bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sesen Bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sesen Bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Sesen Bio Revenue, EBIT and net profit per share

DateSesen Bio Sales per ShareSesen Bio EBIT per shareSesen Bio Earnings per Share
2028e0 undefined0 undefined-0.02 undefined
2027e0 undefined0 undefined-0.02 undefined
2026e0 undefined0 undefined-0.02 undefined
2025e0 undefined0 undefined-0.02 undefined
2024e0 undefined0 undefined-0.03 undefined
2023e0 undefined0 undefined-0.09 undefined
20223.99 undefined1.36 undefined-1.98 undefined
20212.91 undefined3.15 undefined-0.04 undefined
20201.9 undefined-3.57 undefined-3.81 undefined
20190 undefined-1.19 undefined-1.18 undefined
20180 undefined-0.56 undefined-0.55 undefined
20170.02 undefined-1.12 undefined-1.11 undefined
20161.38 undefined0.13 undefined0.09 undefined
20150.05 undefined-1.85 undefined-1.76 undefined
20140.15 undefined-2.25 undefined-2.33 undefined
20130.99 undefined-12 undefined-13.36 undefined
20120 undefined-11.88 undefined-11.99 undefined
20110 undefined-7.73 undefined-7.82 undefined

Sesen Bio business model

Sesen Bio Inc. is a biotechnology company focused on developing advanced therapeutics for the treatment of cancer and other challenging diseases. The company was founded in 2010 in Cambridge, Massachusetts, and has since expanded its research and development efforts to develop a range of therapies based on its innovative technologies and approaches. The goal of Sesen Bio is to develop groundbreaking drugs and therapies that are both safe and effective, helping patients successfully fight their illness. The company's focus is on unlocking new treatment possibilities through its proprietary platforms, including its antibody-drug conjugate (ADC) technology, on which all drug candidates are based. Sesen Bio has three main divisions: cancer treatment, therapy development, and partnership program. The cancer treatment division focuses on clinical trials and product marketing. This is where the first approved drug, Vicinium, is mentioned. Vicinium is an ADC consisting of a monoclonal antibody against prostate-specific membrane antigen (PSMA). It is indicated for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The therapy development division is involved in creating drug candidates and advancing their development through clinical trials. The partnership program allows Sesen Bio to license and commercialize its technologies and platforms by partnering with other biotechnology companies and pharmaceutical companies. The company has made significant progress in the development of therapeutics in recent years. The first approved drug, Vicinium, has propelled the company forward. The company is conducting clinical trials on other drug candidates to evaluate their efficacy and safety. Additionally, the company has a pipeline of new products in various stages of development, including NG-348, a novel ADC targeting the epidermal growth factor receptor (EGFR) that can be used in the treatment of solid tumors in various organs. Sesen Bio aims to further expand its innovative technologies in the field of cancer therapy and expand its offering of groundbreaking therapeutics. The company works closely with its partners and customers to develop customized treatment solutions and ensure high patient satisfaction. With its dedicated research and development department, well-established partnerships, and ability to make groundbreaking technologies widely available, Sesen Bio is on track to become a leading company in the field of cancer therapy. Overall, Sesen Bio is an innovative biotechnology company dedicated to developing therapeutics that improve the lives of patients with cancer and other serious diseases. Through its proprietary technologies and platforms, dedicated research and development departments, and well-established partnerships, the company has established itself as a key player in the field of cancer therapy. Sesen Bio is a company with a vision and a mission that permeate everything it does, namely saving and improving lives. Sesen Bio is one of the most popular companies on Eulerpool.com.

Sesen Bio SWOT Analysis

Strengths

Sesen Bio Inc has an innovative product portfolio that includes advanced therapies in the field of oncology. These therapies have the potential to provide effective treatment options for cancer patients.

The company has a strong and experienced research and development team that continuously strives to develop cutting-edge solutions to address unmet medical needs. This expertise allows Sesen Bio Inc to stay ahead of competitors in the industry.

Weaknesses

Sesen Bio Inc faces the challenge of limited financial resources, which may hinder its ability to significantly invest in research and development activities or expand its market reach. This could slow down the development and commercialization of potential therapies.

Another weakness is the company's limited market presence and brand recognition. Sesen Bio Inc needs to invest in marketing and promotional efforts to increase awareness about its products and establish a strong foothold in the highly competitive oncology market.

Opportunities

The growing demand for advanced oncology therapies presents a significant opportunity for Sesen Bio Inc. By capitalizing on this market trend, the company can expand its product offerings and increase its revenue potential.

Collaboration and strategic partnerships with healthcare institutions, research organizations, or pharmaceutical companies can provide access to additional resources, expertise, and opportunities for the company to accelerate product development and commercialization.

Threats

Sesen Bio Inc operates in a highly regulated industry, making compliance with stringent regulatory requirements a critical concern. Failure to meet these regulations can result in delays or even the inability to bring products to market.

Competition from established pharmaceutical companies and emerging biotech firms poses a threat to Sesen Bio Inc. These competitors may have greater financial resources, well-established distribution networks, and a larger customer base, which can make it challenging for Sesen Bio Inc to gain market share.

Sesen Bio historical P/E ratio, EBIT, and P/S ratio.

Sesen Bio shares outstanding

The number of shares was Sesen Bio in 2023 — This indicates how many shares 10.027 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Sesen Bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sesen Bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sesen Bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sesen Bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Sesen Bio Stock splits

In Sesen Bio's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Sesen Bio.

Sesen Bio list of shareholders

%
Name
Stocks
Change
Date
2.54 % Modernatx Inc5,059,3385,059,3383/8/2023
0.27 % The Vanguard Group, Inc.542,71521212/31/2022
0.23 % Radoff (Bradley Louis)465,00519,2502/13/2023
0.21 % BML Capital Management LLC411,398411,39812/31/2022
0.16 % JEC II Associates, L.L.C.319,9921,0002/13/2023
0.13 % ModernaTX, Inc252,967252,9673/7/2023
0.09 % HealthCap AB178,981178,9813/7/2023
0.07 % BlackRock Institutional Trust Company, N.A.131,280-74,77512/31/2022
0.06 % Geode Capital Management, L.L.C.114,74755612/31/2022
0.03 % Torok (Michael)53,8132,5633/7/2023
1
2
3
4
5
...
10

Most common questions regarding Sesen Bio

What values and corporate philosophy does Sesen Bio represent?

Sesen Bio Inc represents values of innovation, integrity, and commitment to improving patients' lives. With a strong corporate philosophy focused on developing targeted and effective therapies, Sesen Bio Inc aims to address unmet medical needs and enhance patient outcomes. By harnessing the power of its proprietary technology platform, Vicinium, the company strives to deliver breakthrough treatments for solid tumor cancers. Sesen Bio Inc's dedication to scientific advancement and collaboration with healthcare professionals underscores its commitment to finding novel solutions that provide hope for patients worldwide.

In which countries and regions is Sesen Bio primarily present?

Sesen Bio Inc primarily operates in the United States.

What significant milestones has the company Sesen Bio achieved?

Sesen Bio Inc has achieved several significant milestones. The company successfully completed the Phase 3 VISTA trial, which demonstrated the effectiveness of its lead product candidate, Vicinium, for the treatment of non-muscle invasive bladder cancer (NMIBC). Sesen Bio Inc also received Fast Track designation from the FDA for Vicinium, highlighting the potential for expedited development and review. Furthermore, the company expanded its pipeline with the acquisition of BiVictriX Therapeutics, adding innovative antibody-drug conjugate (ADC) technology to its portfolio. Sesen Bio Inc continues to advance its mission of improving the lives of patients through the development of breakthrough therapies.

What is the history and background of the company Sesen Bio?

Sesen Bio Inc, a pharmaceutical company, has a rich history and background. Founded in 1988, the company initially operated as Hybrigenics Corporation before rebranding as Sesen Bio. It specializes in developing innovative therapies for the treatment of various cancers. Sesen Bio is dedicated to improving the lives of patients through its flagship product, Vicinium, a targeted immunotherapy designed to eradicate bladder cancer. With a strong focus on research and development, the company has successfully advanced its pipeline and secured partnerships to further enhance its capabilities. Sesen Bio Inc continues to strive towards delivering novel treatments to address unmet medical needs and making a positive impact on the healthcare industry.

Who are the main competitors of Sesen Bio in the market?

The main competitors of Sesen Bio Inc in the market include various pharmaceutical companies such as Endo International plc, AstraZeneca plc, and Merck & Co., Inc. These competitors operate in the same biotechnology and pharmaceutical industry, focusing on developing and marketing products related to cancer research, development, and treatment. While Sesen Bio Inc has a unique portfolio of targeted fusion protein therapeutics, it competes against these established players for market share and advancements in the field of oncology.

In which industries is Sesen Bio primarily active?

Sesen Bio Inc is primarily active in the biopharmaceutical industry.

What is the business model of Sesen Bio?

The business model of Sesen Bio Inc focuses on the development and commercialization of targeted fusion protein therapeutics for the treatment of cancer. Sesen Bio utilizes its proprietary technology platform to develop novel therapies that selectively target and eliminate cancer cells, while sparing healthy cells. The company's lead product candidate, Vicineum™, is designed to target and treat non-muscle invasive bladder cancer. Sesen Bio's business model centers around advancing its pipeline, conducting clinical trials, obtaining regulatory approvals, and eventually commercializing its innovative therapies to provide improved treatment options for cancer patients worldwide.

What is the P/E ratio of Sesen Bio 2024?

The Sesen Bio P/E ratio is -10.73.

What is the P/S ratio of Sesen Bio 2024?

The Sesen Bio P/S ratio is 0.

What is the AlleAktien quality score of Sesen Bio?

The AlleAktien quality score for Sesen Bio is 1/10.

What is the revenue of Sesen Bio 2024?

The revenue cannot currently be calculated for Sesen Bio.

How high is the profit of Sesen Bio 2024?

The expected Sesen Bio profit is -6.1 M USD.

What is the business model of Sesen Bio

Sesen Bio Inc is a biopharmaceutical company that specializes in the development and marketing of innovative therapies for cancer patients. The company follows a multidimensional business model based on various sectors, including research and development, manufacturing and marketing of cancer drugs, clinical research, and collaboration with the scientific and business community. Sesen Bio aims to improve the treatment of cancer patients and has become a leading company in the field of cancer research and therapy.

What is the Sesen Bio dividend?

Sesen Bio pays a dividend of 0 USD distributed over payouts per year.

How often does Sesen Bio pay dividends?

The dividend cannot currently be calculated for Sesen Bio or the company does not pay out a dividend.

What is the Sesen Bio ISIN?

The ISIN of Sesen Bio is US8177631053.

What is the Sesen Bio WKN?

The WKN of Sesen Bio is A2JL47.

What is the Sesen Bio ticker?

The ticker of Sesen Bio is SESN.

How much dividend does Sesen Bio pay?

Over the past 12 months, Sesen Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sesen Bio is expected to pay a dividend of 0 USD.

What is the dividend yield of Sesen Bio?

The current dividend yield of Sesen Bio is .

When does Sesen Bio pay dividends?

Sesen Bio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sesen Bio?

Sesen Bio paid dividends every year for the past 0 years.

What is the dividend of Sesen Bio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sesen Bio located?

Sesen Bio is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sesen Bio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sesen Bio from 8/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/2/2024.

When did Sesen Bio pay the last dividend?

The last dividend was paid out on 8/2/2024.

What was the dividend of Sesen Bio in the year 2023?

In the year 2023, Sesen Bio distributed 0 USD as dividends.

In which currency does Sesen Bio pay out the dividend?

The dividends of Sesen Bio are distributed in USD.

All fundamentals about Sesen Bio

Our stock analysis for Sesen Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sesen Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.